MOG (35-55): Gold-Standard Peptide for EAE and Multiple Sclerosis Research

Executive Summary: MOG (35-55), derived from human myelin oligodendrocyte glycoprotein, reliably induces experimental autoimmune encephalomyelitis (EAE), the most widely accepted animal model for multiple sclerosis (MS) (APExBIO). The peptide elicits robust T and B cell responses, recapitulating key features of MS pathology, including demyelination and relapsing-remitting neurological symptoms (Xu et al., 2025). Its dose-dependent effects and solubility profile enable precise experimental workflows. MOG (35-55) also modulates redox and matrix remodeling pathways, as indicated by increased NADPH oxidase and MMP-9 activity in vitro. These properties make it a critical tool for mechanistic, translational, and therapeutic studies in autoimmune encephalomyelitis research (see also).

Biological Rationale

Myelin oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin superfamily, expressed on the surface of oligodendrocytes and myelin in the central nervous system (CNS) (APExBIO). The MOG (35-55) peptide, comprising amino acids 35 to 55 of human MOG, contains the dominant encephalitogenic epitope recognized by murine and human immune systems in MS and EAE contexts (see in-depth mechanism). Experimental autoimmune encephalomyelitis (EAE), induced by MOG (35-55), closely reproduces T cell-mediated demyelination and neuroinflammation, core features of MS pathogenesis (Xu et al., 2025). The peptide's use allows researchers to investigate autoimmune mechanisms, neuroimmune crosstalk, and potential therapeutic interventions within a controlled, reproducible model system.

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as an antigenic stimulus, triggering a cascade of adaptive immune responses. Upon administration with complete Freund's adjuvant (CFA), the peptide is taken up by antigen-presenting cells, which process and present the epitope via MHC class II molecules. This interaction activates CD4+ T cells, leading to clonal expansion, cytokine release (notably IFN-γ and IL-17), and recruitment of additional inflammatory cells to CNS tissue (Mechanistic Leverage). B cell activation results in anti-MOG antibodies, further amplifying demyelination. In vitro, MOG (35-55) increases NADPH oxidase and MMP-9 activities, implicating oxidative stress and extracellular matrix remodeling in disease progression (APExBIO). Recent findings demonstrate that modulation of type I interferon signaling (e.g., via PARP7 inhibition) can relieve EAE severity, highlighting the utility of MOG (35-55)-induced EAE for testing immunomodulatory strategies (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) induces robust, relapsing-remitting EAE with demyelination and neurological deficits in C57BL/6 mice at doses of 50–150 μg, with severity increasing dose-dependently (Xu et al., 2025).
• The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, facilitating flexible experimental design and rapid dissolution (APExBIO).
• Administration with CFA leads to strong T and B cell responses, including production of anti-MOG antibodies and CNS infiltration by inflammatory leukocytes (MOG (35-55) Peptide: Next-Gen Insights).
• In vitro, MOG (35-55) reduces protein concentration and increases NADPH oxidase and MMP-9 activities, key markers of oxidative and inflammatory stress (APExBIO).
• PARP7 inhibition in the MOG (35-55) EAE model stabilizes STAT1/STAT2 and reduces clinical severity, validating the model for testing interferon pathway modulators (Xu et al., 2025).
• MOG (35-55) (SKU A8306) is cited as the gold-standard peptide for EAE induction by multiple peer-reviewed and technical sources (Gold-Standard Peptide).

Applications, Limits & Misconceptions

MOG (35-55) is primarily used for:

• Inducing EAE in rodents to model MS pathogenesis.
• Testing immunotherapies targeting T cell, B cell, or cytokine pathways.
• Assessing neuroinflammation and demyelination dynamics using in vivo and ex vivo assays.
• Screening pharmacological agents affecting redox or matrix remodeling pathways.

However, its use is bounded by several factors:

Common Pitfalls or Misconceptions

• Species-Specificity: MOG (35-55) induces EAE reliably in certain mouse strains (e.g., C57BL/6) but not all rodent models or higher mammals; results may not extrapolate to humans.
• Solubility Constraints: Peptide is insoluble in ethanol; improper solvent use can lead to aggregation and reduced immunogenicity (APExBIO).
• Model Scope: While EAE mimics many features of MS, it does not capture all aspects, such as cortical demyelination or progressive non-relapsing forms of the disease (Scenario-Driven Solutions).
• Dose Titration: Exceeding recommended doses (>150 μg/mouse) may cause excessive morbidity or mortality, confounding study endpoints.
• Storage and Degradation: Degraded peptide (improper storage, multiple freeze-thaw cycles) leads to reduced efficacy and inconsistent EAE induction.

Workflow Integration & Parameters

For reliable induction of EAE, MOG (35-55) should be dissolved in sterile water at 0.50 mg/mL, with warming and ultrasonic bath treatment to enhance solubility (MOG (35-55) protocol). The peptide should be stored desiccated at -20°C and used promptly after reconstitution to prevent degradation. Subcutaneous injection of 50–150 μg per mouse, emulsified in CFA, is standard for EAE induction in C57BL/6 mice. Disease onset typically occurs 9–14 days post-immunization, with severity assessed via neurological scoring and weight monitoring. In vitro assays (e.g., NADPH oxidase, MMP-9 activity) require accurate dosing and buffer compatibility. The A8306 kit from APExBIO includes validated purity and technical support for reproducibility. This article extends the guidance given in Scenario-Driven Solutions for Reliable EAE by providing molecular benchmarks and application limits.

Conclusion & Outlook

MOG (35-55) remains the gold standard for preclinical MS modeling due to its defined mechanism and reproducible outcomes. Its use enables high-fidelity studies of neuroinflammation, immune modulation, and therapeutic efficacy in the context of MS and related autoimmune diseases. Ongoing research, including studies on interferon signaling modulation and PARP7 inhibition, continues to validate and extend the relevance of MOG (35-55)-induced EAE (Xu et al., 2025). For advanced experimental designs, refer to MOG (35-55) and the Next Wave of Translational MS Research, which this article updates with the latest mechanistic and workflow insights.